ELI LILY
AACI
This critical trial explores Donanemab‘s potential in preventing the progression of early Alzheimer’s disease by targeting amyloid plaques in the brain. This N3pG antibody aims to halt or slow cognitive decline. This study holds promise for early intervention in Alzheimer’s disease’s progression.
Status: ACTIVE, NOT RECRUITING